Sie suchten nach: rilpivirinom (Kroatisch - Englisch)

liječeni rilpivirinom
rilpivirine-treated

iskustvo predoziranja rilpivirinom u ljudi je ograničeno.
human experience of overdose with rilpivirine is limited.

nije dokazana teratogenost s rilpivirinom u štakora i kunića.
there was no teratogenicity with rilpivirine in rats and rabbits.

kad se započinje primjena metadona istovremeno s rilpivirinom, nije potrebna prilagodba doze.
no dose adjustments are required when initiating co-administration of methadone with rilpivirine.

supstitucija e138k pojavljivala se najčešće tijekom liječenja rilpivirinom, obično u kombinaciji sa supstitucijom m184i.
the e138k substitution emerged most frequently during rilpivirine treatment, commonly in combination with the m184i substitution.

do supstitucije e138k došlo je najčešće tijekom liječenja rilpivirinom, obično u kombinaciji s m184i supstitucijom.
the e138k substitution emerged most frequently during rilpivirine treatment, commonly in combination with the m184i substitution.

istodobna primjena lijeka kaletra s rilpivirinom uzrokuje povišenje koncentracije rilpivirina u plazmi, ali nije potrebno prilagođavanje doze.
concomitant use of kaletra with rilpivirine causes an increase in the plasma concentrations of rilpivirine, but no dose adjustment is required.

nije potrebna prilagodba doze rilpivirina kad se atazanavir/kobicistat ili darunavir/kobicistat primjenjuju istodobno s rilpivirinom.
no dose adjustment of rilpivirine is required when atazanavir/cobicistat or darunavir/cobicistat are used concomitantly with rilpivirine.

srednje vrijednosti u skupini liječenoj rilpivirinom i za bazalni i za acth-om stimulirani kortizol u 96. tjednu bile su unutar normalnog raspona.
mean values for the rilpivirine arm for both basal and acth-stimulated cortisol at week 96 were within the normal range.

pedeset dva postotka hiv-1 izolata s novonastalom rezistencijom u skupini liječenoj rilpivirinom razvilo je istodobne nnrti i nrti mutacije, najčešće e138k i m184v.
fifty-two percent of hiv-1 isolates with emergent resistance in the rilpivirine arm developed concomitant nnrti and nrti mutations, most frequently e138k and m184v.

+226 x 106 stanica/l u skupini liječenoj rilpivirinom i +222 x 106 stanica/l u skupini liječenoj efavirenzom.
222 x 106 cells/l for the rilpivirine and efavirenz treatment arms, respectively, of patients receiving the emtricitabine/tenofovir disoproxil fumarate background regimen.

u 96. tjednu incidencija virološkog neuspjeha bila je viša u skupini liječenoj rilpivirinom nego u skupini liječenoj efavirenzom; međutim većina viroloških neuspjeha pojavila se tijekom prvih 48 tjedana liječenja.
the incidence of virologic failure was higher in the rilpivirine arm than the efavirenz arm at week 96; however, most of the virologic failures occurred within the first 48 weeks of treatment.

10 830 nm (920 do 3 970 ng/ml), ne preporučuje se liječenje hiv-2 infekcije rilpivirinom obzirom da nema kliničkih podataka.
10,830 nm (920 to 3,970 ng/ml), treatment of hiv-2 infection with rilpivirine is not recommended in the absence of clinical data.

liječenje rilpivirinom rezultiralo je ranim blagim porastom srednje vrijednosti razina kreatinina u serumu koja je ostala stabilna tijekom vremena te se nije smatrala klinički značajnom (vidjeti dio 4.8).
treatment with rilpivirine resulted in an early small increase of mean serum creatinine levels which remained stable over time and is not considered clinically relevant (see section 4.8).

liječenje predoziranja rilpivirinom sastoji se od općih potpornih mjera koje uključuju nadzor vitalnih znakova i ekg-a (qt interval), kao i praćenje kliničkog stanja bolesnika.
treatment of overdose with rilpivirine consists of general supportive measures including monitoring of vital signs and ecg (qt interval) as well as observation of the clinical status of the patient.

interakcije između lijekova ocijenjene su za režim liječenja lijekom viekirax i dasabuvirom, ali ne i za režim liječenja lijekom viekirax bez dasabuvira, s karbamazepinom, furosemidom, zolpidemom, darunavirom dvaput na dan, darunavirom (primjena navečer), atazanavirom (primjena navečer), rilpivirinom, abakavirom/lamivudinom, dolutegravirom, metforminom, sulfametoksazolom/trimetoprimom, ciklobenzaprinom, karisoprodolom, hidrokodonom/paracetamolom ili diazepamom.
drug interactions were evaluated for the viekirax and dasabuvir regimen, but not for the viekirax without dasabuvir, with carbamazepine, furosemide, zolpidem, darunavir twice daily, darunavir (evening administration), atazanavir (evening administration), rilpivirine, abacavir/lamivudine, dolutegravir, metformin, sulfamethoxazole/trimethoprim, cyclobenzaprine, carisoprodol, hydrocodone/ paracetamol or diazepam.